Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

PURPOSE: Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatment, efficacy and safety were comparable between treatments. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Stebbing, Justin, Baranau, Yauheni V., Baryash, Valery, Manikhas, Alexey, Moiseyenko, Vladimir, Dzagnidze, Giorgi, Zhavrid, Edvard, Boliukh, Dmytro, Pikiel, Joanna, Eniu, Alexandru E., Li, Rubi K., Tiangco, Beatrice, Lee, Sang Joon, Kim, Sunghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272708/
https://www.ncbi.nlm.nih.gov/pubmed/34148205
http://dx.doi.org/10.1007/s10549-021-06240-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272708/
https://www.ncbi.nlm.nih.gov/pubmed/34148205
http://dx.doi.org/10.1007/s10549-021-06240-5

Ejemplares similares